* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download rajiv gandhi university of health sciences
Survey
Document related concepts
Plateau principle wikipedia , lookup
Orphan drug wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Psychopharmacology wikipedia , lookup
Compounding wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Nicholas A. Peppas wikipedia , lookup
Neuropharmacology wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Drug design wikipedia , lookup
Prescription costs wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Theralizumab wikipedia , lookup
Drug interaction wikipedia , lookup
Drug discovery wikipedia , lookup
Transcript
RAJIV GANDHI UNIVERSITY OF HEALTH SCIENCES, BANGALORE, KARNATAKA ANNEXURE – II PROFORMA FOR REGISTRATION OF SUBJECT FOR DISSERTATION 1. NAME OF THE CANDIDATE AND ADDRESS Mr. SHAIKH MUZAMMIL SAGEER DEPARTMENT OF PHARMACEUTICS, K.L.E. SOCIETY’s COLLEGE OF PHARMACY, J. N. M. C. CAMPUS, NEHRU NAGAR, BELGAUM – 590010, KARNATAKA. 2. NAME OF THE INSTITUTION 3. COURSE OF STUDY AND SUBJECT 4. DATE OF ADMISSION TO K.L.E. SOCIETY’s COLLEGE OF PHARMACY, J. N. M. C. CAMPUS, NEHRU NAGAR, BELGAUM – 590010, KARNATAKA. MASTER OF PHARMACY IN PHARMACEUTICS JUNE 2007 COURSE “STERICALLY STABILIZED 5. TITLE OF THE TOPIC LIPOSOMAL DRUG DELIVERY SYSTEM FOR DOXORUBICIN-DESIGN AND CHARACTERIZATION” 1 6. BRIEF RESUME OF THE INTENDED WORK: 6.1 NEED FOR THE STUDY: The concept of drug delivery to a particular site for the treatment of localized disease in the body and thereby decreasing adverse effect of drug with improving its therapeutic index is being considered as a challenge in modern formulation design1. So, constant efforts have been persued in order to design such an ideal drug delivery system which improves therapeutic index of drugs and also improves patient compliance. One such area which has attracted increasing attention of pharmaceutical scientist and has shown very promising results is “Targeted Drug Delivery System”2. Amongst all carriers utilized for target oriented drug delivery, vesicular drug delivery system in form of liposomes is most extensively investigated. Liposome has been regarded as a beneficial carrier system for parental application of variety of drugs due to their biocompatible and biodegradable properties. Though liposomes have been proved to be versatile carrier for wide variety of drug, there are two major inherent drawbacks of conventional liposomes i.e. Rapid uptake of drug carrier by phagocytic cells of RES. Poor or shorter circulation time [3-5]. The inherent drawback of conventional liposome can be overcome by using a novel approach of surface modification by using sterically stabilized liposomes or “Stealth Liposome”. The most promising result of liposome modification were achieved for avoiding RES detection and prolonging retention in circulation by covalent attachment of hydrophilic polymer groups to the liposome surface to inhibit interaction with blood proteins and other plasma components 2 and thus liposome uptake by the macrophage system is inhibited. And there is an increase in their circulation time. Longer circulation of liposome in blood resulted in higher uptake of drug in an implanted tumor 6-8. Doxorubicin is an anticancerous agent used in breast cancer, ovarian cancer, AIDS related Kaposi’s sarcoma. The therapeutic efficacy of doxorubicin is restricted by dose limiting toxicity to bone marrow and heart tissue9. The selective toxicity of doxorubicin could be greatly improved if the concentration of drug in tumors could be increased relative to that in sensitive normal tissues10. Hence, in the present work, an attempt is being made to develop sterically stabilized liposomal formulation of doxorubicin which will have following advantages. Selective passive targeting to tumor tissues. Increased efficacy and therapeutic index. Reduction in toxicity of encapsulated drug. Avoidance of RES uptake of drug carrier composite. Increased circulatory time thus enhanced stability. 6.2 REVIEW OF LITERATURE Literature review for undertaking the study was done by referring to various national and international journals, published articles in various official standard books and referring to various websites on the internet. Attempt was done to study passive targeting of doxorubicin with polymer coated liposomes in tumor bearing rats. The study revealed that polymers having a hydrophobic moiety in the molecule such as PVA-R and HPMC-R are suitable materials for modifying the surfaces of the doxorubicin-loaded liposome to improve its targeting property11. Study on preparation, characterization and pharmacokinetics of N-palmitoyl chitosan 3 anchored docetaxel liposome was done. The study revealed that anchored liposomes could increase the stability of docetaxel in-vivo, as compared with plain liposomes, but the improvement was not more significant than PEGylated liposomes. N-palmitoyl chitosan as a new polymeric membrane to anchor liposome was useful to stabilize liposomes containing anti-tumor drug12. A study was conducted on Haloperidol-associated stealth liposomes. The study demonstrated that haloperidol-targeted gene delivery systems can mediate efficient targeting of genes to sigma receptor-over expressing breast cancer cells, thereby becoming a novel class of therapeutics for the treatment of human cancers13. An attempt was made to study Doxorubicin-loaded fab fragments of antidisialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. It was concluded that fab-SIL[DXR] formulations led to the total inhibition of metastatic growth of human NB in a nude mouse metastatic model. This formulation should receive clinical evaluation as adjuvant therapy of NB14. A study was conducted on therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. The study stated that Liposome-encapsulated drugs at and below therapeutic concentrations were more effective than free drug against tuberculosis, as evaluated on the basis of CFUs detected, organomegaly, and histopathology. Furthermore, liposomal drugs had marginal hepatotoxicities as determined from the levels of total bilirubin and hepatic enzymes in serum. The elimination of mycobacteria from the liver and spleen was also higher with liposomal drugs than with free drugs. The encapsulation of antitubercular drugs in lung specific stealth liposome seems to be a promising therapeutic approach for the chemotherapy of tuberculosis15. 4 6.3 OBJECTIVES OF THE STUDY 1. Preformulation studies. 2. Preparation of Stealth liposomes by using Thin film hydration method or any other suitable / appropriate method16. 3. Characterization of formulated stealth liposomes for following parameters. i. ii. Physical Characterization a. Vesicle size and surface morphology.----TEM b. Vesicle size and size distribution.---SEM17 c. Surface charge.---ZETA MEATER 18 d. Lamellarity.----NMR e. Phase behavior.----DSC 19 f. In – Vitro drug release. g. In – Vivo tissue distribution study20. h. In – Vivo tissue tumor study Chemical Characterizations. a. Phospholipids concentration by using HPLC. b. Cholesterol concentration by using HPLC. c. pH by using pH meter. d. Drug concentration by using appropriate methods as per the individual monograph. e. Stability studies as per ICH guidelines21. 5 7. MATERIALS AND METHODS Drug : Doxorubicin. Carrier : Egg-Phosphatidyl Choline (EPC), Dimyristoryl phosphatidyl choline (DMPC), Distearoyl phosphatidyl choline (DSPC), PE-PEG. Excipients : Cholesterol, Stearyl amine, Polyvinyl Alcohol and its derivative bearing a hydrophobic anchor (PVA-R)/ Hydroxy methyl cellulose and its derivative having hydrophobic moiety (HPMC-R). Method : Preparation of Stealth liposomes by Thin film hydration method or any other suitable / appropriate method16. 7.1 SOURCE OF DATA: This data is obtained from the prepared Stealth liposomes drug delivery system of doxorubicin based on the laboratory experiment and evaluation. 7.2 METHOD OF COLLECTION OF DATA: i. Physical Characterization a. Vesicle size and surface morphology----TEM. b. Vesicle size and size distribution----SEM17 c. Surface charge----Zeta meter18 d. Lamellarity. e. Phase behavior----DSC19 f. In – Vitro drug release. g. In – Vivo tissue distribution study20. h. In – Vivo tissue tumor 6 ii. Chemical Characterizations. a. Phospholipids concentration by using HPLC. b. Cholesterol concentration by using HPLC. c. pH by using pH meter. c. Concentration by using appropriate methods as per the individual monograph. e. Stability studies as per ICH guidelines21. 7.3 Does the study require any investigations or invention to be conducted on patients or other human or animals? If so, please mention briefly. Yes ( Wistar rats) 7.4 Has ethical clearance been obtained from your institution in case of 7.3? Yes 8. REFERENCES 1. Vyas SP, Singh RP, Jain S, Mishra V, Mohar S, Singh P et al. Non-ionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis-B. Int J Pharm 2005; 296:80-6. 2. Chein YW. Fundamentals of rate controlled drug delivery: Novel drug delivery system. New York (NY): Marcel Dekker Inc.; 1992;43-137. 3. Poste G, Bucana C, Raz A, Bugelski P, Kirsh R, Fidler IJ. Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res 1982; 42:1412-22. 4. Senior JH. Critical reviews in therapeutic drug carrier systems. Biol Pharmaceut Bull 1987;3:123-93. 7 5. Papahadjopoulos D., Gabizon A., Targeting of liposomes to tumor cells in vivo. Ann NY Acad Sci 1987;507:64-74. 6. Poznansky M, Juliano RL. Biological approaches to the controlled delivery of drugs: A critical review. Pharmacol Rev 1984;36:277-336. 7. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A 1988; 85(18): 6949-53. 8. Gabizon, A, Shiota R, Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst 1989; 81(19):1484-8. 9. Allen TM, Mehra T, Hansen CB, Chin YC. Stealth liposomes: an improved sustained release system for 1-β-D-arabinofuranosylcytosine. Can Res 1992; 52: 2431-2439. 10. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-92. 11. Takeuchi H, Kojima H, Yamamoto H, Kawashima Y. Passive targeting of Doxorubicin with polymer coated liposomes in tumor bearing rats. Biol Pharm Bull 2001; 24(7): 795-9 12. Liang G, Jia-Bi Z, Fei X, Bin N. Preparation, characterization and pharmacokinetics of N-palmitoyl chitosan anchored docetexal liposomes. J Pharm Pharmacol 2007; 59: 661-7. 13. Mukherjee A, Prasad TK, Rao NM, Banerjee R. Haloperidol-associated stealth liposomes: a potent carrier for delivering genes to human cancer cells. J Biol Chem 2005; 280(16):15619-27. 14. Pastorino F, Brignole C, Marimpietri. Sapra P, Moase EH, Allen TM et al. Doxorubicin-loaded fab, fragments of anti-disialonganglioside immunoliposomes selectivity inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 2003;63:86-92. 15. Deol P, Khuller GK, Joshi K. Therapeutic efficacies of Isoniazid and Rifampin encaposulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemotherap 1997; 41(6):1211-4. 8 16. Vyas SP. Khar RK. Targeted and Controlled Drug Delivery: Novel Carrier System. New Delhi: CBS Publishers and Distributors; 2002:182-4. 17. Arunothayanun P, Unchebu IF, Craig DQM, Tutron JA. In vitro/in vivo characterization of polyhedral niosomes. Int J Pharm 1999;183:57-61 18. Benoit JP, Bouligand Y, Lampercht A. “New lipid nanocapsules exhibit sustained release properties for Amiodarone. J. Control Rel. 2002;84:59-68. 19. Molpeceres J, Aberturas MR, Guzman M. Biodegradable nanoparticles as a delivery system for cyclosporine: preparation and characterization. J Microencap 2000;17(5): 599-614. 20. Prego C, Torres D, Megia FE, Caballal NR, Quinoa E, Alonso MJ. Chitosan –PEG nanocapsules as new carriers for oral peptide delivery effect of chitosan pegylation degree. J Control Rel 2006;111:299-308. 21. Carstensen JT. Drug stability: Principle and practice. New York: Marcel Dekker Inc; 1995:538-50. 9 9. Signature of Candidate 10. Remarks of the guide 11. The above information is true to the best of my knowledge and the work will be done under my guidance. Dr. RAJENDRA C. DOIJAD 11.1 Name and Designation of Guide M. Pharm., Ph.D PROFESSOR, Department of Pharmaceutics, K.L.E. Society’s College of Pharmacy, J. N. M. C. Campus, Nehru Nagar, Belgaum – 590010, Karnataka. 11.2 Signature 11.3 Co-Guide (IF ANY) 11.4 Signature 11.5 Head of the Department Dr. F. V. MANVI M. Pharm., Ph.D PRINCIPAL, K.L.E. Society’s College of Pharmacy, J. N. M. C. Campus, Nehru Nagar, Belgaum – 590010, Karnataka. 11.6 Signature 12. 12.1 Remarks of the Chairman and Principal The above mentioned information is correct and I recommend the same for approval. 12.2 Signature Dr. F. V. MANVI M. Pharm., Ph.D PRINCIPAL, K.L.E. Society’s College of Pharmacy, J. N. M. C. Campus, Nehru Nagar, Belgaum – 590010, Karnataka. 10